Centre for the Advancement of Sustainable Medical Innovation
 | |
| Founded | 2012 |
|---|---|
| Focus | Medical innovation, pharmaceutical R&D, life science regulation |
Key people | Sir John Bell, Sir John Tooke, Dr Richard Barker |
| Website | www |
The Centre for the Advancement of Sustainable Medical Innovation (CASMI)[1] is a collaboration between University of Oxford and University College London, created to develop new models for medical innovation. The centre aims to address the issues that have led to current failures in the translation of basic bioscience into affordable and widely adopted new treatments.
Leadership
Sir John Bell – Co-chair
Sir John Tooke – Co-chair
Richard Barker – Director
Fellows
Oxford Fellows
Professor Houman Ashrafian
Professor Chas Bountra
Professor Sir Rory Collins
Professor Kay Davies
Professor Sue Dopson
Professor Andrew Farmer
Professor Adrian Hill
Professor Stephen MacMahon
Professor Robyn Norton
Professor Michael Parker
Professor Len Seymour
Professor Hugh Watkins
UCL Fellows
Professor Nick Freemantle
Professor Dame Hazel Genn
Professor Aroon Hingorani
Professor Robert Horne
Professor Philip Luthert
Professor Quentin Pankhurst
Professor Rosalind Raine
Professor David Taylor
Professor Bryan Williams
Professor Martin Utley
Projects
Adaptive licensing
CASMI is leading an evaluation of whether the UK would be a suitable test site for a potential adaptive licensing[2] pilot through the European Medicines Agency. This was recently announced in the government's ‘Strategy for UK Life Sciences: One Year On’ report.[3] The project was initiated by a workshop held at the Wellcome Trust on 2 April 2012.
Stratified medicine
CASMI is developing recommendations on how the regulatory environment and pharmaceutical R&D process should be adapted to the needs of stratified medicine[4] and companion diagnostics.
Regulation of cell therapy
CASMI, supported by the Technology Strategy Board, is investigating current and anticipated regulatory obstacles to the successful commercialisation of cell-based therapies, seeking to integrate the opinion of key stakeholders to support the development of a sustainable and globally competitive UK cell therapy industry.[5]
Partners
SENS Foundation
Technology Strategy Board
University of Oxford
UCL
Wellcome Trust
Recent publications
Adaptive drug development and licensing, Richard Barker & Sarah Garner, Regulatory Rapporteur. Oct 2012[6]
A flexible blueprint for the future of drug development, Richard Barker, Lancet. Jan 2010[7]
References
- ^ "CASMI website". CASMI. Retrieved 2013-01-28.
- ^ "Adaptive licensing project page, CASMI website". CASMI. Retrieved 2013-01-28.
- ^ http://www.bis.gov.uk/assets/biscore/innovation/docs/s/12-1346-strategy-for-uk-life-sciences-one-year-on.pdf |title=Industrial Strategy: government and industry in partnership |author=HM Government
- ^ "Stratified medicine project page, CASMI website". CASMI. Retrieved 2013-01-28.
- ^ "Cell-based therapies project page, CASMI website". CASMI. Retrieved 2013-01-28.
- ^ "Archived copy" (PDF). Archived from the original (PDF) on 2013-01-02. Retrieved 2012-12-10.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help)CS1 maint: archived copy as title (link) |agency=Regulatory Rapporteur |coauthors=Dr Richard Barker, Sarah Garner - ^ Original TextRichard Barker a. "A flexible blueprint for the future of drug development". The Lancet. Retrieved 2013-01-28.